



4 October 2022

Clarification to ASX announcement of 28 September 2022

Opyl Limited (ASX:OPL) provides details of the grounds for marking its announcement dated 28 September 2022 entitled "New strategic partnership & new research screening service" as not material for the purposes of Listing Rule 3.1.

New strategic partnership

The company does not consider the strategic partnership with Consentia to be 'material' as it is too early to "reasonably" determine expected revenues/take-up. The strategic partnership with Consentia has no minimum revenue target. There is a positive commitment to collaborate, to promote each other to existing and new customers and, share any revenue per the revenue-share (a fixed capped percentage of the project value) and referral fee arrangement.

New research screening service

Similarly, it is too early to "reasonably" determine expected revenues from this new research screening service which expands the Company's offering and functionality across the digital/virtual trial recruitment activity value chain, building towards full service and improving the Company's competitive position.

Opin, the Company's clinical recruitment tool, continues to evolve and this strategic partnership coupled with the new research screening service is intended to increase the opportunities to grow revenue.

The Board has authorised this announcement for release to the ASX.

-ENDS-

For media and investor enquiries: info@opyl.ai

For clinical trial recruitment enquiries: info@opin.ai

www.opyl.ai

www.opin.ai

Opyl is a new generation Australian digital health company that applies artificial intelligence to improving clinical trials. Our platforms make clinical trials more efficient and easier to access, giving patients more options and saving medical researchers time and money.

Our key offering for biopharma, medtech, government and healthcare organisations:

- clinical trial recruitment solutions – Opin.ai
- clinical trial predictive analytics and protocol design – Trial Key
- deep social media insights and analysis – Social Insights

Follow Opyl on Twitter (@Opylai), LinkedIn and Facebook